danirixin
Small moleculeexperimental
Clinical trial activity
15 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2009 (NCT01209052)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor BANTAGONIST
CXCR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O- Mol. weight
- 441.91 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039531 ↗
Also known as
- danirixin
- danirixin
- danirixin
- danirixin
- gsk1325756
- gsk1325756
- gsk1325756
- gsk1325756b
- gsk1325756b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03457727 | Phase 1 | Mar 7, 2018 | GlaxoSmithKline |
| NCT03250689 | Phase 2 | Nov 15, 2017 | GlaxoSmithKline |
| NCT03170232 | Phase 2 | Sep 11, 2017 | GlaxoSmithKline |
| NCT03136380 | Phase 1 | May 10, 2017 | GlaxoSmithKline |
| NCT03034967 | Phase 2 | Apr 26, 2017 | GlaxoSmithKline |
| NCT02927431 | Phase 2 | Jan 1, 2017 | GlaxoSmithKline |
| NCT02469298 | Phase 2 | Jun 1, 2015 | GlaxoSmithKline |
| NCT02453022 | Phase 1 | May 18, 2015 | GlaxoSmithKline |
| NCT02169583 | Phase 1 | Jun 12, 2014 | GlaxoSmithKline |
| NCT02130193 | Phase 2 | Feb 13, 2014 | GlaxoSmithKline |
| NCT02201303 | Phase 1 | Jan 13, 2014 | GlaxoSmithKline |
| NCT01453478 | Phase 1 | Oct 12, 2011 | GlaxoSmithKline |
| NCT01267006 | Phase 1 | Nov 1, 2010 | GlaxoSmithKline |
| NCT01209104 | Phase 1 | Apr 14, 2010 | GlaxoSmithKline |
| NCT01209052 | Phase 1 | Oct 15, 2009 | GlaxoSmithKline |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 15 | 15 | 2 | 2009 |
1 organizations
Page 1 / 1